ANX is up 11.66%, but it still needs to close its Oct 1 DG.<g>
bigcharts.marketwatch.com
Its lead product candidate, ANX-510,is in PIII & PIIb trials for the treatment of metastatic colorectal Ca & in a PII for the treatment of advanced breast Ca.
Its ANX-530,is in a clinical trial for the treatment of NSCLC
Besides those two, ANX also has ANX-513, which is a paclitaxel emulsion for possible treatment of ovarian & NSCLC;
ANX-514, which is a docetaxel emulsion for possible treatment of breast, NSCLC, prostate & gastric Cas.
It also has some drugs for possible treatment of IDs, like its
ANX-201 for HIV; ANX-015, which is a clarithromycin emulsion,an IV formulation of clarithromycin &ANX-016, whichb is a vancomycin emulsion.
ANX trades around 1.8xBV; the insiders reportedly hold > 15%; it doesn't have significant LTD, but has a negative CF around $0.35 & is expected to have persistent losses in 2007 & 2008 around $0.25/shr.
If ANX could get to close its Oct DG & trade up to the $1 level, it would be a good % gain from present levels.<g>
bigcharts.marketwatch.com
Bernard |
